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Background: Stem cell therapy has shown benefit for peripheral arterial disease (PAD) patients who are not amenable to conventional 
revascularization. However, the lack of sustained engraftment and the difficulty to non-invasively monitor and track the fate of infused cells in 
vivo hinders stem cell therapeutic applications. Cell microencapsulation with addition of imaging contrast agents provides a novel means to 
provide cell immunoprotection and simultaneously enable cell tracking with non-invasive imaging. We present here a novel MRI- and CT- visible 
perfluorooctylbromide (PFOB) microcapsules (PFOB Caps) for mesenchymal stem cell (MSC) delivery and engraftment tracking using clinical imaging 
scanners.
Methods: Microencapsulation of rabbit MSCs with PFOB-loaded alginate was performed using an electrostatic droplet generator. Control capsules 
lacked PFOB. In vitro MSC viability was assessed using a fluorometric assay. Microencapsulated or naked MSCs were intramuscularly delivered into 
the medial thigh of the rabbit PAD model (n=16). X-ray angiograms, c-arm CT, and 19F MR images were taken within 1-14 days after administration. 
The representation of PFOB Cap injections with radiopacities on c-arm CT and hotspots on 19F MRI was validated with postmortem histology. In vitro 
phantom studies were performed to determine the minimum detectable number of PFOB Caps using c-arm CT and 19F MRI.
Results: The viability of rabbit MSCs within PFOB Caps showed a small decline immediately after encapsulation (90±3%) and remained high 
up to 4 weeks post-encapsulation (88±5%). In vivo detection of PFOB Caps with c-arm CT images was confirmed in 95% of the injections in PAD 
rabbits. 19F MRI was able to detect 100% of PFOB Cap sites seen on c-arm CT. 5% of PFOB Cap injection sites were not detectable by either imaging 
technique, indicating injection failure which was confirmed by postmortem evaluation. In vitro, 19F MRI and c-arm CT were able to detect as few as 
5 and 2 PFOB Caps, respectively.
Conclusion: PFOB microencapsulation of MSC is a novel approach for maintaining cell viability, and for the first time enabling the monitoring of 
MSC delivery and tracking in vivo using clinical noninvasive imaging.
